ArticleClinical and experimental pediatrics2026
Serum metabolomic profile in children with sepsis-associated acute kidney injury.
Article in Clinical and experimental pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated acute kidney injury (SA-AKI) contributes to high morbidity and mortality rates in children; however, current diagnostic tools (serum creatinine and urine output) lack sensitivity for early detection. Metabolomics can be used to discover novel metabolic markers to enable early diagnosis and prognosis and provide therapeutic targets for SA-AKI. Purpose: This study was aimed to identify the differentially expressed serum metabolites in children with SA-AKI. Methods: We conducted an untargeted serum metabolomic analysis using liquid chromatography-mass spectroscopy (LC-MS) in 75 children: 45 with sepsis and acute kidney injury (AKI) (15 each in Kidney Disease Improving Global Outcomes [KDIGO] stages 1-3), 15 with sepsis without AKI, and 15 healthy controls. Fasting blood samples were collected and centrifuged. Supernatant serum was stored at -80°C and subjected to untargeted metabolomic analysis using LC-MS. Reverse-phase and hydrophilic liquid interaction chromatographic separation was performed in positive and negative ion scan modes, while metabolite identification was performed using the SCIEX All-In-One HR-MS/MS Library with National Institute of Standards and Technology 2017 Library bundle. Results: The significantly altered metabolites in AKI stage 3 were lipids belonging to the glycerophosphoethanolamine subgroup of the phospholipid class. Eighteen metabolites were differentially expressed in patients with SA-AKI versus healthy controls, with phosphoethanolamines (e.g., 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine) showing a consistent association with AKI stage. Thirty-one metabolites were significantly altered in severe AKI (KDIGO stages 2-3), of which only 4 could be annotated and increased proportionally with AKI severity. A pathway analysis revealed significant enrichment of glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism in stage 3 SA-AKI. Conclusion: Serum metabolomics is a feasible approach to identifying novel biomarkers of SA-AKI. Phosphoethanolamine metabolites both distinguished AKI from sepsis controls and were correlated with clinical severity (estimated glomerular filtration rate decline), suggesting its potential prognostic value. However, its diagnostic feasibility requires preliminary validation in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.